Overview

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Status:
Active, not recruiting
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Green Cross LabCell Corporation
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Rituximab
Vidarabine